Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

Holly L. Pacenta, Margaret E. Macy

Research output: Contribution to journalReview article

Abstract

RTK plays important roles in many cellular signaling processes involved in cancer growth and development. ALK, TRKA, TRKB, TRKC, and ROS1 are RTKs involved in several canonical pathways related to oncogenesis. These proteins can be genetically altered in malignancies, leading to receptor activation and constitutive signaling through their respective downstream pathways. Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, and despite intensive therapy, there is a high mortality rate in cases with a high-risk disease. Alterations of ALK and differential expression of TRK proteins are reported in a proportion of NB. Several inhibitors of ALK or TRKA/B/C have been evaluated both preclinically and clinically in the treatment of NB. These agents have had variable success and are not routinely used in the treatment of NB. Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibitor with activity against tumors with ALK, NTRK1, NTRK2, NTRK3, and ROS1 alterations in Phase I clinical trials in adults. Entrectinib’s activity against both ALK and TRK proteins suggests a possible role in NB treatment, and it is currently under investigation in both pediatric and adult oncology patients.

Original languageEnglish (US)
Pages (from-to)3549-3561
Number of pages13
JournalDrug Design, Development and Therapy
Volume12
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Neuroblastoma
Neoplasms
Therapeutics
Clinical Trials, Phase I
Proteins
Growth and Development
Carcinogenesis
entrectinib
Pediatrics
Mortality

Keywords

  • ALK
  • entrectinib
  • Neuroblastoma
  • ROS1
  • TRK

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. / Pacenta, Holly L.; Macy, Margaret E.

In: Drug Design, Development and Therapy, Vol. 12, 01.01.2018, p. 3549-3561.

Research output: Contribution to journalReview article

@article{404268a7c3f74fd79bdc562332207a7a,
title = "Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma",
abstract = "RTK plays important roles in many cellular signaling processes involved in cancer growth and development. ALK, TRKA, TRKB, TRKC, and ROS1 are RTKs involved in several canonical pathways related to oncogenesis. These proteins can be genetically altered in malignancies, leading to receptor activation and constitutive signaling through their respective downstream pathways. Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, and despite intensive therapy, there is a high mortality rate in cases with a high-risk disease. Alterations of ALK and differential expression of TRK proteins are reported in a proportion of NB. Several inhibitors of ALK or TRKA/B/C have been evaluated both preclinically and clinically in the treatment of NB. These agents have had variable success and are not routinely used in the treatment of NB. Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibitor with activity against tumors with ALK, NTRK1, NTRK2, NTRK3, and ROS1 alterations in Phase I clinical trials in adults. Entrectinib’s activity against both ALK and TRK proteins suggests a possible role in NB treatment, and it is currently under investigation in both pediatric and adult oncology patients.",
keywords = "ALK, entrectinib, Neuroblastoma, ROS1, TRK",
author = "Pacenta, {Holly L.} and Macy, {Margaret E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/DDDT.S147384",
language = "English (US)",
volume = "12",
pages = "3549--3561",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

AU - Pacenta, Holly L.

AU - Macy, Margaret E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - RTK plays important roles in many cellular signaling processes involved in cancer growth and development. ALK, TRKA, TRKB, TRKC, and ROS1 are RTKs involved in several canonical pathways related to oncogenesis. These proteins can be genetically altered in malignancies, leading to receptor activation and constitutive signaling through their respective downstream pathways. Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, and despite intensive therapy, there is a high mortality rate in cases with a high-risk disease. Alterations of ALK and differential expression of TRK proteins are reported in a proportion of NB. Several inhibitors of ALK or TRKA/B/C have been evaluated both preclinically and clinically in the treatment of NB. These agents have had variable success and are not routinely used in the treatment of NB. Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibitor with activity against tumors with ALK, NTRK1, NTRK2, NTRK3, and ROS1 alterations in Phase I clinical trials in adults. Entrectinib’s activity against both ALK and TRK proteins suggests a possible role in NB treatment, and it is currently under investigation in both pediatric and adult oncology patients.

AB - RTK plays important roles in many cellular signaling processes involved in cancer growth and development. ALK, TRKA, TRKB, TRKC, and ROS1 are RTKs involved in several canonical pathways related to oncogenesis. These proteins can be genetically altered in malignancies, leading to receptor activation and constitutive signaling through their respective downstream pathways. Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, and despite intensive therapy, there is a high mortality rate in cases with a high-risk disease. Alterations of ALK and differential expression of TRK proteins are reported in a proportion of NB. Several inhibitors of ALK or TRKA/B/C have been evaluated both preclinically and clinically in the treatment of NB. These agents have had variable success and are not routinely used in the treatment of NB. Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibitor with activity against tumors with ALK, NTRK1, NTRK2, NTRK3, and ROS1 alterations in Phase I clinical trials in adults. Entrectinib’s activity against both ALK and TRK proteins suggests a possible role in NB treatment, and it is currently under investigation in both pediatric and adult oncology patients.

KW - ALK

KW - entrectinib

KW - Neuroblastoma

KW - ROS1

KW - TRK

UR - http://www.scopus.com/inward/record.url?scp=85056527131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056527131&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S147384

DO - 10.2147/DDDT.S147384

M3 - Review article

C2 - 30425456

AN - SCOPUS:85056527131

VL - 12

SP - 3549

EP - 3561

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -